For UPSA, choosing “Made in France” means proving that another path is possible: one of a sustainable and responsible economy for future generations. It’s a commitment to strengthening our health and industrial sovereignty—ensuring zero shortages for our patients, creating jobs, and contributing to social cohesion across our regions. It’s a choice to green our industry. And it’s a choice to promote our know-how on the international stage.
For 90 years, UPSA has been manufacturing its medicines in France, in the Lot-et-Garonne region. It is precisely this local anchoring that defines our uniqueness, as we choose year after year to invest in our industrial facilities, in our R&D capabilities, and in the excellence of our employees. The results? Today, we are the leading manufacturer of paracetamol-based medicines in France and the first pharmaceutical laboratory to obtain the Origine France Garantie certification. And our ambition goes further: to produce our medicines with 100% French-sourced paracetamol.
Choosing “Made in France” means contributing to both healthcare and industrial sovereignty. By producing our medicines in Agen, we ensure zero shortages for our patients even during periods of strain, guaranteeing uninterrupted access to their treatments. We create jobs on our sites and indirectly throughout our supplier network. Finally, we support projects within our ecosystem, thereby contributing sustainably to the social cohesion of local communities.
UPSA becomes the first pharmaceutical laboratory certified Origine France Garantie for all of its medicines. The Origine France Garantie certification is now officially recognized as a demanding label for products made in France.
Another key impact of choosing “Made in France” is the reduction of our environmental footprint at the local level. To source our materials, UPSA prioritizes short supply chains. Today, 80% of our suppliers are based in France.
We are also investing to rebuild a fully French supply chain for the production of paracetamol’s active ingredient through two major projects: one with chemical manufacturer Seqens in Roussillon (Auvergne-Rhône-Alpes), and the other with Toulouse-based start-up Ipsophene in Occitanie.
Our long-term goal: to rely exclusively on French-produced paracetamol.
Greening our industry also means making substantial investments to improve the energy efficiency of our industrial sites in Agen — including the installation of heat pumps and photovoltaic canopies over parking areas.
On the product side, UPSA is committed to eco-design: 75% of our products (by volume) have already undergone a Life Cycle Assessment.
Through a unique interactive experience, discover the behind-the-scenes of how our products are made.
Finally, “Made in France” is a true mark of quality on the international stage, reflecting the heritage of our expertise and our capacity for innovation. UPSA already exports more than 57% of its volumes to over 60 countries across Europe, Africa, and Asia.
This “France label” enables us to conquer new markets, such as our recent expansions in China, Kenya, and Saudi Arabia. Ultimately, it contributes to enhancing France’s global influence.
Choosing “Made in France” is an ambitious and demanding path. But in our view, it is the only path toward a sustainable and responsible economy. And it is ours — for well-being, quality of life, and responsible action.
UPSA promotes the “Made in France” label in 60 countries.
